Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Increase In Operating Expenses In Q3

Loading news article.

Amgen Exec Says Spent $500M In Q2 On Capital Expenditures, Driven By Investments Across U.S. Manufacturing Sites; Continues To Expect Capital Expenditures Of About $2.6B In 2026 To Scale Manufacturing Capacity, Including For Maritide's Launch; Expect A Meaningful Sequential Increase In Operating Expenses In Q3 | WAPE

Article summary

Related companies

Comments —